Agonists and Antagonists
While cannabis clinicians reported reduced use of pharmaceuticals by their patients, a major pharmaceutical company developed a drug to counter the munchies that works by blocking the cannabinoid receptor.
- Therapeutic Potential in Spotlight as ICRS Meets in Canada
- Orange (County) Curtain lifted by Denney and Sullivan
- Cannabis in the Curriculum at USC Keck School of Medicine
- Implementation of the Compassionate Use Act in a Family Medical Practice by Frank Lucido and M. Mangini
- Cannabis Use in Adolescence: Self-Medication for Anxiety by Tom O’Connell, MD
- Center for Medicinal Cannabis Research has 18 Studies in Pipeline by Dale Gieringer
- Clinical Observations by Tod Mikuriya, Philip A. Denney, and Tom O’Connell
- Reduced Use of Pharmaceuticals a Recurring Theme by Jeffrey Hergenrather
- Which Conditions Might be Treatable With Cannabis?
- Ricky Williams Protests Drug Testing by Quitting Football
- ICRS 2004: Cannabinoid Antagonist Will be Sold as Diet Drug
- The Rimonabant Rump Session*
- Honor Complexity by Andrew Weil, MD
- The Prosecution of Tod Mikuriya, MD
- Jane Weirick Attributes Illness to Pesticide Exposure from Cannabis Trimming
- Dr. Leveque’s Unspoken Message to Congress
- Privacy Wins in Bearman Case
- A Reluctant Martyr: Marian Fry, MD
- The Context of Prohibition
- A Pro-Cannabis Doctor ‘Comes Out’ (Carol Wolman, MD)
- Painful Lessons from the DEA’s War on Opioid Prescribers by Joe Talley, MD
- Ashcroft v. Raich: The U.S. Supreme Court Case in Context by Fred Gardner
- Cases Riding on Raich and Booker Rulings by Ann Harrison
- CHP Insists on Disrespecting Prop 215
- California’s Medical Marijuana Law: Landmark Cases by Omar Figueroa and Pebbles Trippet
- Vioxx Deaths = 55,000 (Why Do They Hate You?)
- On the Prosecution of Pain-Treating Physicians by Frank Fisher, MD
- Cities and Counties Impose Restrictions but Cannabis Clubs Keep Opening by Dale Gieringer
*scroll down for Rimonabant exposé
Description
Description
In which a major pharmaceutical company conducts clinical trials of a weight-loss drug that suppresses appetite by blocking the cannabinoid receptor. And cannabis clinicians continue to document reduced use of pharmaceuticals by their patients.
- Therapeutic Potential in Spotlight as ICRS Meets in Canada
- Orange (County) Curtain lifted by Denney and Sullivan
- Cannabis in the Curriculum at USC Keck School of Medicine
- Implementation of the Compassionate Use Act in a Family Medical Practice by Frank Lucido and M. Mangini
- Cannabis Use in Adolescence: Self-Medication for Anxiety by Tom O’Connell, MD
- Center for Medicinal Cannabis Research has 18 Studies in Pipeline by Dale Gieringer
- Clinical Observations by Tod Mikuriya, Philip A. Denney, and Tom O’Connell
- Reduced Use of Pharmaceuticals a Recurring Theme by Jeffrey Hergenrather
- Which Conditions Might be Treatable With Cannabis?
- Ricky Williams Protests Drug Testing by Quitting Football
- ICRS 2004: Cannabinoid Antagonist Will be Sold as Diet Drug
- The Rimonabant Rump Session*
- Honor Complexity by Andrew Weil, MD
- The Prosecution of Tod Mikuriya, MD
- Jane Weirick Attributes Illness to Pesticide Exposure from Cannabis Trimming
- Dr. Leveque’s Unspoken Message to Congress
- Privacy Wins in Bearman Case
- A Reluctant Martyr: Marian Fry, MD
- The Context of Prohibition
- A Pro-Cannabis Doctor ‘Comes Out’ (Carol Wolman, MD)
- Painful Lessons from the DEA’s War on Opioid Prescribers by Joe Talley, MD
- Ashcroft v. Raich: The U.S. Supreme Court Case in Context by Fred Gardner
- Cases Riding on Raich and Booker Rulings by Ann Harrison
- CHP Insists on Disrespecting Prop 215
- California’s Medical Marijuana Law: Landmark Cases by Omar Figueroa and Pebbles Trippet
- Vioxx Deaths = 55,000 (Why Do They Hate You?)
- On the Prosecution of Pain-Treating Physicians by Frank Fisher, MD
- Cities and Counties Impose Restrictions but Cannabis Clubs Keep Opening by Dale Gieringer
*scroll down for Rimonabant exposé